Cargando…

Interdisciplinary model‐informed drug development for extending duration of elagolix treatment in patients with uterine fibroids

AIM: Elagolix, a gonadotropin‐releasing hormone receptor antagonist, was recently approved for heavy menstrual bleeding associated with uterine fibroids (UF, Oriahnn) at a dose of 300 mg twice daily (BID) in combination with add‐back therapy (oestradiol 1 mg/norethindrone acetate 0.5 mg [E2/NETA] on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beck, Denise, Winzenborg, Insa, Gao, Wei, Mostafa, Nael M., Chiuve, Stephanie E., Owens, Charlotte, Shebley, Mohamad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796281/ https://www.ncbi.nlm.nih.gov/pubmed/35695781 http://dx.doi.org/10.1111/bcp.15440

Ejemplares similares

Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids
por: Beck, Denise, et al.
Publicado: (2021)

Integrating real‐world data and modeling to project changes in femoral neck bone mineral density and fracture risk in premenopausal women
por: Beck, Denise, et al.
Publicado: (2021)

Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis
por: Shebley, Mohamad, et al.
Publicado: (2019)

Validation of a quantitative systems pharmacology model of calcium homeostasis using elagolix Phase 3 clinical trial data in women with endometriosis
por: Stodtmann, Sven, et al.
Publicado: (2021)

Effects of elagolix on the pharmacokinetics of omeprazole and its metabolites in healthy premenopausal women
por: Nader, Ahmed, et al.
Publicado: (2022)

Exposure‐Safety Analyses Identify Predictors of Change in Bone Mineral Density and Support Elagolix Labeling for Endometriosis‐Associated Pain
por: Abbas Suleiman, Ahmed, et al.
Publicado: (2020)

Effect of Elagolix Exposure on Clinical Efficacy End Points in Phase III Trials in Women With Endometriosis‐Associated Pain: An Application of Markov Model
por: Winzenborg, Insa, et al.
Publicado: (2020)

Efficacy and safety of elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosis
por: Muneyyirci-Delale, Ozgul, et al.
Publicado: (2021)

A Personalized Medicine Approach Using Clinical Utility Index and Exposure‐Response Modeling Informed by Patient Preferences Data
por: Winzenborg, Insa, et al.
Publicado: (2020)

Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids
por: Al-Hendy, Ayman, et al.
Publicado: (2021)

Reduction of Heavy Menstrual Bleeding in Women Not Designated as Responders to Elagolix Plus Add Back Therapy for Uterine Fibroids
por: Stewart, Elizabeth A., et al.
Publicado: (2022)

Assessment of Clinical Drug‐Drug Interactions of Elagolix, a Gonadotropin‐Releasing Hormone Receptor Antagonist
por: Polepally, Akshanth R., et al.
Publicado: (2020)

Uterine fibroids and incidence of depression, anxiety and self-directed violence: a cohort study
por: Chiuve, Stephanie E, et al.
Publicado: (2022)

Clinical Utility Of Elagolix As An Oral Treatment For Women With Uterine Fibroids: A Short Report On The Emerging Efficacy Data
por: Neri, Manuela, et al.
Publicado: (2019)

Elagolix treatment in women with heavy menstrual bleeding associated with uterine fibroid: a systematic review and meta-analysis
por: Muhammad, Juliawati, et al.
Publicado: (2022)

Physiologically based pharmacokinetic modeling and simulations to inform dissolution specifications and clinical relevance of release rates on elagolix exposure
por: Mukherjee, Dwaipayan, et al.
Publicado: (2022)

Quantitative Assessment of Elagolix Enzyme-Transporter Interplay and Drug–Drug Interactions Using Physiologically Based Pharmacokinetic Modeling
por: Chiney, Manoj S., et al.
Publicado: (2019)

Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas
por: Simon, James A., et al.
Publicado: (2020)

Phase 2, double-blind, randomized, placebo-controlled study of the safety and efficacy of elagolix in women with polycystic ovary syndrome
por: Snabes, Michael C., et al.
Publicado: (2023)

Elagolix: First Global Approval
por: Lamb, Yvette N.
Publicado: (2018)

Uterine Fibroids
Publicado: (1903)

A Clinician's Guide to the Treatment of Endometriosis with Elagolix
por: Leyland, Nicholas, et al.
Publicado: (2021)

Safety after extended repeated use of ulipristal acetate for uterine fibroids
por: Fauser, Bart C. J. M., et al.
Publicado: (2017)

Correction to: Elagolix: First Global Approval
por: Lamb, Yvette N.
Publicado: (2018)

Operations on Uterine Fibroids
Publicado: (1901)

The Treatment of Uterine Fibroids
por: Hicks, H. T.
Publicado: (1907)

The Treatment of Uterine Fibroids
Publicado: (1900)

The Treatment of Uterine Fibroids
Publicado: (1903)

Uterine Fibroids and Diet
por: Tinelli, Andrea, et al.
Publicado: (2021)

Uterine Fibroids and Infertility
por: Freytag, Damaris, et al.
Publicado: (2021)

Treatment of Uterine Fibroids
por: Goelet, Augustin H.
Publicado: (1894)

The Treatment of Uterine Fibroids
por: Hardon, Virgil O.
Publicado: (1902)

Uterine Fibroids or Myomata
por: Myers, J. F.
Publicado: (1903)

Uterine fibroids in pregnancy
por: Sobel, Mara, et al.
Publicado: (2022)

Treatment of Uterine Fibroids
por: Dunsmoor, F. A.
Publicado: (1899)

The Treatment of Uterine Fibroids
Publicado: (1894)

Quality Information about Uterine Fibroids on the Internet
por: Melo, Daniela Gama de, et al.
Publicado: (2018)

Uterine Fibroid Embolisation for Symptomatic Uterine Fibroids: A Survey of Clinical Practice in Europe
por: Voogt, Marianne J., et al.
Publicado: (2010)

Uterine anteversion after uterine fibroid embolization
por: Raissi, Driss, et al.
Publicado: (2018)

Complications of Uterine Fibroids and Their Management
por: Fletcher, Horace, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_onvp4t66bp5mipjfmcrrjm99jk